Chemotherapy-induced Neutropenia Clinical Trial
Official title:
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced Febrile Neutropenia in Iranian Cancer Patients
The present study was an observational, multicenter, non-interventional, single arm, open
label, PMS study conducted in Iran.
The primary objective of this study was safety assessment, including the rate of AEs. The
secondary objective was the effectiveness evaluation in the prevention of
chemotherapy-induced FN.
The present study was an observational, multicenter, non-interventional, single arm, open
label, PMS study conducted in Iran.
Data was gathered in two booklets, each containing information on four cycles of
chemotherapy, which was filled by the designated physician. The duration of PegaGen®
treatment was at the physicians' discretion based on the patient's condition.
The primary objective of this study was safety assessment, including the rate of AEs. The
secondary objective was the effectiveness evaluation in the prevention of
chemotherapy-induced FN.
This study was single arm and 654 subjects participated across various tumor types and
regimens.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02643901 -
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT02454530 -
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
|
||
| Completed |
NCT02251977 -
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02104830 -
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients
|
Phase 3 | |
| Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
| Active, not recruiting |
NCT03294577 -
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
|
Phase 3 | |
| Not yet recruiting |
NCT03701841 -
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
|
||
| Completed |
NCT00776165 -
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
|
Phase 3 | |
| Completed |
NCT03251768 -
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
| Completed |
NCT04134429 -
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
|
||
| Completed |
NCT04227990 -
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
|
Phase 2 | |
| Completed |
NCT03102606 -
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
|
Phase 3 | |
| Completed |
NCT01569087 -
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients
|
Phase 2 | |
| Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
| Recruiting |
NCT02725606 -
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
|
Phase 1 | |
| Completed |
NCT02692742 -
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
|
Phase 2 | |
| Completed |
NCT02532712 -
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01516736 -
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
|
Phase 3 | |
| Terminated |
NCT04887831 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
|
Phase 2 |